HCA HCA Healthcare, Inc. Insider Trading

McAlevey (EVP & Chief Legal & Admin Off.) sold 1,694 shares of HCA at $533.37; holdings drop to 8,853 shares.

Michael R. McAlevey, EVP & Chief Legal & Administrative Officer at HCA Healthcare, sold 1,694 shares at $533.37 on 2026-02-18, reducing his holdings by 16.1% to 8,853 shares and raising $903,536.74. The sale occurs near the 52-week high of $540.29 (within -1.0%), and HCA's stock has gained 14.0% over the prior 30 days and 12.3% over 90 days, suggesting a backdrop of near-peak valuations. However, McAlevey's cross-ticker track record shows a 90-day well-timed rate of 0.00%, and his single prior HCA sale (2025-11-05) delivered a 90-day return of +5.4%, indicating the stock rose after his last sale. HCA fundamentals remain solid with $19.2B in latest quarterly revenue, $1.6B net income, and a reasonable 16.24 P/E ratio, so the sale does not signal fundamental concern. The transaction appears routine relative to the executive's modest historical engagement in open-market activity.

HCA SVP/Chief HR Officer Berres sells 8,020 shares across 2 transactions for $4,126,950.05

Jennifer Berres, SVP and Chief Human Resources Officer, executed 2 separate sales totaling 8,020 shares for $4,126,950.05 on 2026-02-11, at blended average price of $514.58. This represents a -40.1% reduction in her HCA holdings, bringing her remaining stake to 11,993 shares. The timing of the sales coincides with HCA trading near its 52-week high ($535.22 current price, +0.0% from 52-week high), and follows the stock's strong 30-day (+11.7%) and 90-day (+13.2%) appreciation. Her prior sales at HCA (2 trades on 2025-02-14) yielded positive 90-day returns (+19.4% and +19.6%), indicating the stock has historically moved higher after her sells at this ticker. The company's fundamentals remain solid with $19.2B in quarterly revenue, $1.6B net income, and +7.1% annual revenue growth.

SVP & Controller Wyatt Christopher F. sold 4,000 HCA shares at $505.00 on 2026-02-11 for $2.0M

Wyatt Christopher F., SVP & Controller, sold 4,000 shares (-8.3% of pre-transaction holdings) at $505.00, reducing his HCA position from 48.4K to 44.4K shares. The transaction occurred as HCA stock stands at $535.22, off its 52-week low of $306.30 and matching its 52-week high, with strong recent momentum (+11.7% in 30 days, +13.2% in 90 days). His prior two sales at HCA in 2024 both showed positive 90-day returns (+0.9% and -1.5%, with only 1 of 2 well-timed at the 90-day mark), and cross-ticker his track record shows a 50% well-timed rate on sells with average 90-day negative return of -0.3%. The timing of this sale—at the 52-week high with sustained upward momentum—presents a contrasting signal compared to HCA fundamentals, which show revenue of $19.2B and net income of $1.6B with 7.1% annual revenue growth and a moderate P/E of 16.24.

HCA Healthcare CEO Samuel N. Hazen sells 42,877 shares for $21.5M, reducing stake by 72.8%

On 2026-02-03, Samuel N. Hazen, HCA Healthcare's CEO, executed 7 separate sales totaling 42,877 shares for $21,483,274.82 at a blended average price of $501.04, reducing his post-transaction holdings to 16,024 shares from 58,901 shares. This represents a 72.8% reduction in the CEO's personal stake at a time when HCA's stock trades near its 52-week highs ($513.76 current vs. $515.85 52-week high, -0.4%), suggesting the sale occurred during a strong valuation environment. The fundamentals backdrop shows HCA generated $19.2B in revenue and $1.6B in net income on an 8.7% annual growth trajectory, with the company trading at a P/E of 18.48 and market cap of $117.2B. The magnitude and structure of this divestiture—a substantial reduction in the CEO's ownership concentration—warrants examination of whether this reflects portfolio rebalancing, tax planning, or potential shifts in the CEO's strategic positioning.

EVP & Chief Legal & Admin Officer sold 3,892 shares of HCA at $473.79, reducing holdings 52.7% to 3,487 shares

Michael R McAlevey, EVP & Chief Legal & Administrative Officer, sold 3,892 shares (3.9K shares) of HCA Healthcare at $473.79 on 2025-11-05, resulting in total proceeds of $1,843,990.68 ($1.8M). This transaction reduced his post-transaction holdings to 3,487 shares (3.5K shares), representing a -52.7% reduction from pre-transaction holdings of 7,379 shares (7.4K shares). The sale occurred at the 52-week high of $473.20, with HCA's stock up 9.2% over 30 days and 26.8% over 90 days, reflecting sustained positive momentum in the security. As a senior legal and administrative officer at a $108.0B market cap healthcare company with solid fundamentals—$19.2B quarterly revenue, $1.6B net income, and 8.7% annual revenue growth—the significant reduction in personal holdings warrants attention for potential changes in executive positioning or liquidity needs.

HCA Chief Clinical Officer Cuffe sold 3,836 shares at $418.84 for $1.6M, reducing HCA stake by -10.9%.

Cuffe Michael S., EVP and Chief Clinical Officer, sold 3,836 shares (3.8K shares) of HCA Healthcare, Inc. (HCA) at $418.84 on 2025-09-08 for total value of $1,606,670.24 ($1.6M), reducing his post-transaction holdings to 31,502 shares (31.5K shares) from pre-transaction 35,338 shares (35.3K shares), a net reduction of -10.9% vs pre-transaction holdings. The sale occurs as HCA trades at $418.10, just -0.6% from its 52-week high of $420.77 and up +9.6% over the past 30 days and +14.6% over 90 days, reflecting strong recent momentum. Examining his same-ticker history at HCA across 3 prior sells, 2 of 3 prior sells were well-timed at the 90-day mark, though outcomes vary: a 2024-09-12 sale had -18.2% 90d return (well-timed), while a 2024-05-09 sale had +11.2% 90d return (poorly timed). This current sale near the 52-week high deserves tracking to assess whether this executive's pattern of measured occasional sales at inflated valuations continues.

EVP and COO Foster sells 15.7K HCA shares at $369.32; holds 72.3K post-transaction

Foster Jon M, EVP and COO of HCA Healthcare, sold 15,698 shares for $5,797,660.71 on 2025-05-13, reducing his holdings from 88,006 shares to 72,308 shares. The sale occurred when HCA traded at $369.32, currently sitting at $385.50 (up 14.9% over the past 30 days and 21.9% over 90 days). At a P/E of 16.05 and with the company posting 8.7% annual revenue growth and $1.6B in net income on $18.3B quarterly revenue, HCA remains well-capitalized and operationally sound. The 17.8% reduction in Foster's holdings is proportionally meaningful but leaves him with substantial remaining position, consistent with a partial reduction in a large executive stake rather than a fundamental exit.

BofA (10% owner) net bought 258 shares in HCA via 13 buys and 17 sales totaling $88.2K buys, $79.8K sales, over 9 months (Jul 2011–Apr 2012).

Bank of America, as a 10% owner of HCA Healthcare, executed a protracted sequence of 30 separate buy and sell transactions across nine months (July 2011 through April 2012), with 13 purchases totaling $88,208.25 and 17 sales totaling $79,816.40 resulting in a net position of 258 shares acquired. The individual transactions ranged from single-digit to 1,300-share lots at prices spanning $21.90 to $29.00 per share, suggesting ongoing portfolio-level rebalancing or systematic hedging rather than a concentrated conviction-based position move. The high turnover—with frequent buy-sell pairs on identical or near-identical price points (e.g., $26.58 sold and bought on 2012-01-25, $25.31/$25.32 sold and $25.46 bought on 2012-02-22)—is consistent with operational hedging or structural rebalancing by a large owner rather than discretionary market-timing activity. With HCA trading at a 13.18 P/E and posting 8.7% annual revenue growth on $17.5B in revenue, the modest net accumulation does not signal a material shift in conviction by this 10% stakeholder.

HCA Healthcare SVP & Chief HR Officer Jennifer Berres sold 9,533 shares (38.2% of holdings) for $3,075,240.24 on 2025-02-14

Berres executed 2 separate sales on 2025-02-14 totaling 9,533 shares for $3,075,240.24 at a blended average price of $322.59, reducing her post-transaction holdings to 15,412 shares from 24,945 shares. The transaction occurred when HCA's stock trades at $316.71, only 1.8% below her execution prices and near its 30-day high (+2.0%), suggesting the sale was not executed during a depressed window. At 12.20 P/E and $17.5B in quarterly revenue with +8.7% annual growth, HCA remains a financially stable large-cap health care operator; the sale represents a meaningful reduction in this insider's concentrated position rather than a signal about the underlying business.

SVP-Internal Audit sells 3,897 HCA shares at $350.00; retains 52,702 shares post-transaction

Billington Phillip G, SVP-Internal Audit Services, sold 3,897 shares (3.9K shares) at $350.00 on 2024-11-14, reducing his position by 6.9% to 52,702 shares. The transaction occurred as HCA's stock has declined 16.8% from its 52-week high of $415.54 and fallen 13.9% over the past 30 days, suggesting the sale occurred against a backdrop of recent weakness. Billington remains a substantial holder with over 52,700 shares, indicating continued material ownership despite the sale. HCA's fundamentals remain solid with $17.5B in quarterly revenue, $1.3B net income, and a P/E of 14.76, providing context that the stock weakness is not accompanied by deteriorating operational performance.